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Synopsis: 15 
There is a growing global concern regarding the rise of antibiotic resistant organisms.  Many of these 16 
reports have focused on various Gram-positive and Gram-negative pathogens, with little attention to 17 
the genus Ureaplasma.  Ureaplasma spp. are associated with numerous infectious diseases affecting 18 
pregnant women, neonates and the immune compromised.  Treatment options are extremely limited 19 
due to high levels of intrinsic resistance resulting from the unique physiology of these organisms, and 20 
further restricted in cases of the developing fetus or neonate often limiting therapeutic options to 21 
predominantly macrolides, or rarely fluoroquinolones.  The increasing presence of macrolide and 22 
fluoroquinolone resistant strains among neonatal infections may result in pan-drug resistance and 23 
potentially untreatable conditions.  Here we review the requirements for accurate measurement of 24 
antimicrobial susceptibility, provide a comprehensive review of the antimicrobial resistance (AMR) for 25 
Ureaplasma species in the literature, and contextualize these results relative to some investigator’s 26 
reliance on commercial kits that are not CLSIlinical Laboratory Standard Institute compliant when 27 
determining AMR. The dramatic variation in the resistance patterns and impact of high levels of AMR 28 
amongst neonatal populations suggests the need for continued surveillance.  Commercial kits represent 29 
an excellent tool for initial antibiotic susceptibility determination and screening.  However, AMR 30 
reporting must utilize internationally-standardised methods as high titre samples, or M. hominis-31 
contaminated samples, routinely give false AMR results. Furthermore, requirement for future reports 32 
to determine the underlying AMR mechanisms will determine if expanding AMR is due to spontaneous 33 
mutation, transmission of resistance genes on mobile elements or selection and expansion of resistant 34 
clones. 35 
 36 
Introduction: Ureaplasma as a pathogen  37 
A focus on the ESKAPE pathogens, multi-drug resistant Mycobacterium tuberculosis and drug resistant 38 
Neisseria gonorrhoeae predominate both the scientific literature and the media with little attention 39 
drawn to some of the less prominent pathogens.  This relative lack of attention does not correlate to the 40 
absence of a problem.  Ureaplasma are some of the smallest self-replicating organisms known to inhabit 41 
the human host.  As the name suggests they possess a unique capacity to utilize urea as a primary carbon 42 
source in the generation of ATP.1  Within the genus two human associated species exist: Ureaplasma 43 
urealyticum and Ureaplasma parvum and predominantly differ in the genomic coding capacity 44 
(0.75−0.78 Mbp versus 0.84−0.95 Mbp genomes).2  Ureaplasma spp. have had a controversial history 45 
as a pathogen in part due the high colonization rate among healthy individuals with 40 – 80 % of healthy 46 
females being colonized.  Ureaplasma are now recognized pathogens among pregnant females, 47 
neonates, sexually active individuals and the immunocompromised.3, 4  One of the most recent reports 48 
have identified a link between individuals suffering from hyperammonemia following lung 49 
transplantation and systemic infection by Ureaplasma spp.5   50 
 51 
Therapeutic options 52 
Treatment of Ureaplasma spp. infections are complicated by high levels of intrinsic resistance to many 53 
commonly prescribed antimicrobials; for example the lack of a cell wall confers resistance to all beta-54 
lactam and glycopeptide antibiotics whereas the lack of de novo synthesis of folic acid renders cells 55 
resistant to sulphonamides and diaminopyrimidines.   56 
 57 
Only four classes of antibiotics are recognized for the treatment of Ureaplasma infections.  These are 58 
notably those which belong to the fluoroquinolone, tetracycline, chloramphenicol and macrolide 59 
classes.  When considering infections among pregnant females or neonates the number of therapeutic 60 
options are further restricted due to accumulation of tetracyclines in developing bones, “grey baby 61 
syndrome” associated with chloramphenicol and reticence in using fluoroquinolones in neonates.  62 
Therefore emergence of macrolide resistant strains threaten to severely limit treatment of Ureaplasma 63 
infections among these individuals, especially as Ureaplasma fluoroquinolone resistance is present and 64 
expanding in Europe.6   65 
 66 
Administration of antibiotics has been associated with both clinical and microbiological cure in clinical 67 
presentations.  In a study by Bharat et al., resolution of hyperammonemia was correlated with 68 
administration of azithromycin or levofloxacin resulting in subsequent microbiological cure.5  In a 69 
single case the patient did not respond to azithromycin treatment, but this was later attributed to the 70 
presence of a macrolide resistant strain. In some instances chloramphenicol has been used in the 71 
treatment of Ureaplasma induced meningitis among both adults and neonates, although potential 72 
complications surrounding toxicity in systemic use needs to be balanced with clinical outcome.7, 8  73 
Although favorable results have been noticed in many studies, the use of antibiotics among individuals 74 
with suspected non-gonococcal urethritis (NGU) as a result of Ureaplasma spp. infection is still 75 
questionable.  A study by Khosropour et al., noted that 57% of individuals with NGU who were initially 76 
infected with Ureaplasma spp. and received antimicrobial therapy with initially azithromycin (1g) 77 
followed by doxycycline (100 mg twice daily for seven days), or vice versa, were still colonized after 78 
six weeks of therapy.9     79 
 80 
These data suggest in many cases it is possible to manage infections caused by Ureaplasma, when 81 
dealing with antibiotic susceptible strains.  As highlighted by this review antibiotic resistant strains of 82 
Ureaplasma are present within the community.  The mechanisms of resistance vary accordingly 83 
depending on the antibiotic in question.  Accumulation of point mutations in the 23S rRNA genes and 84 
the quinolone resistance determining regions (QRDRs) of the parC genes are the predominant 85 
mechanisms of resistance to macrolides and fluoroquinolones, respectively with acquisition of the gene 86 
encoding the Tet(M) ribosomal protection protein on the Tn916-like mobile element being associated 87 
with resistance to tetracycline.6  The detailed mechanisms of resistance are beyond the scope of this 88 
review.  89 
 90 
Determining antibiotic susceptibility profiles for Ureaplasma spp 91 
isolates using Clinical Laboratory Standards Institute (CLSI) guidelines 92 
and commercially available kits 93 
Routine antimicrobial susceptibility testing (AST) for Ureaplasma is rarely performed due to the 94 
fastidious nature and specialized growth medium requirements.  Therefore, most infections are treated 95 
empirically, utilizing molecular methods for test of cure.  For this reason, AST is predominantly 96 
conducted for surveillance purposes, in the development of novel antimicrobials or clinical cases where 97 
patients fail to respond to treatment.10 98 
 99 
AST has been reported for Ureaplasma over numerous decades.  In 2001, the publication Cumitech 34, 100 
outlined not only diagnostic methods for uUreaplasmas and Mmycoplasmas, but also detailed 101 
standardized methods for AST.  However, in 2011 an international collaboration to standardize ASTM 102 
for Ureaplasma spp, M. hominis and M. pneuomoniaepneumoniae was published by the Clinical and 103 
Laboratory Standards Institute (CLSI).  CLSI M43-A highlights the requirement for standardized media 104 
(10B broth or A8 agar) quality control isolates (U. urealyticum [SV9] ATCC® 33175™ in the case of 105 
Ureaplasma) and reference ranges for determining susceptibility or resistance.   106 
 107 
Although standardized methodologies exist there is still a lack of routine AST.  One factor which may 108 
contribute to the lack of routine AST maybe the complex nature of testing regimes.  Ureaplasmas are 109 
unable to grow as confluent lawns on bacteriological agar plates therefore negating the use of commonly 110 
used disk-diffusion assays, therefore broth microdilution and agar dilutions methods are favored, 111 
although these have their drawbacks.  The inability to grow Ureaplasma to a turbid culture, owing to 112 
the self-toxic nature of metabolites produceds as well as small cell size, means that McFarland standards 113 
are not available for standardizing inoculum size.  Broth culture methods can utilize an increase in pH 114 
in the medium which increases from pH=6.5 to pH>8.0 caused by the conversion of urea to ammonium 115 
ions by Ureaplasma, changing the phenol red in the medium from yellow-orange to cerise red.  To 116 
achieve the required 104 – 105 CFUcfu/ml mL inoculum for reliable susceptibility testing, cultures 117 
require predetermination of CFU cfu prior to AST with freezing of the culture of known inoculum so 118 
that numbers can be adjusting accordingly.  This can be a lengthy process which delays reporting of the 119 
isolates antibiogram.  Routine clinical laboratories cannot feasibly accommodate setting these methods, 120 
even if the complex routine medium can be obtained commercially, it is too labor intensive and requires 121 
specialized training of staff.  This is where the commercially available Ureaplasma AST kits find their 122 
niche.  123 
       124 
Commercial kits provide a streamlined and simplistic approach to detection of Ureaplasma spp and 125 
AST.  These kits contain dried antibiotic powders at two breakpoint concentrations which become 126 
reconstituted upon inoculation.  Although these kits can be sourced from a range of suppliers, caution 127 
must be exercised when interpreting the results because there are a number of factors that do not comply 128 
with the approved CLSI guidelines.  Firstly, none of these kits utilize a dilution method of accurately 129 
quantifying the inoculum which is added to the test panel.  Although some kits have separate wells that 130 
can differentiate inoculum levels of > 104 CFUcfu/specimen, they utilize an undisclosed method of 131 
inhibition as no physical dilution prior to addition to these wells occurs in the sample preparation (Table 132 
1).  It is well established that a load greater than 105 will give a false-resistant result.6  Assay, such as 133 
the MIST2, gives a semi-quantitative result of either positive or > 104.  This assay will therefore not 134 
differentiate if there is a high bacterial load of greater than the recommended 105 which has been 135 
documented to be as high as 107 in a number of samples.11  136 
 137 
Secondly commercial kits cannot separate results for Ureaplasma and Mycoplasma hominis mixed 138 
cultures.12  Due to the intrinsic resistance of M. hominis to macrolides it is impossible to determine if 139 
Ureaplasma sp in these mixed samples are susceptibleensitive to macrolides.13  This has led to the 140 
unfortunate false-resistance reporting by investigators that note higher rates of macrolide resistance 141 
among sample with co-isolation of both organisms12, as they did not do follow-up investigations on 142 
Ureaplasma isolates purified from the M. hominis contamination.  For reliable susceptibility testing it 143 
is essential to isolate a purified culture of test isolate.  144 
 145 
The most important shortfall in the commercial AST kits is the use of test concentrations different from 146 
the CLSI-determined breakpoints.  Interpretation guidance provided with these kits define (1) growth 147 
in growth control, with negative result in either concentration of antibiotic indicates a susceptible 148 
isolate; (2) growth in the growth control and  lower antibiotic concentration but not the higher suggests 149 
intermediate susceptibility;  and (3) growth in all conditions suggest full resistance.  Unfortunately the 150 
concentrations in many of these kits do not match those defined by CLSI documentation:  CLSI 151 
designate the erythromycin breakpoint as growth at greater or equal to 16 mg/L erythromycin suggests 152 
a resistant isolate, whereas the BioMerieux kit utilizes 4 mg/L, four-fold less than recommended.  This 153 
may lead to over-reporting macrolide resistance among studies which have utilized the MIST2 kit, a 154 
topic which is discussed later.  Conversely the breakpoint for tetracycline stated by CLSI has been stated 155 
as 2 mg/L whereas the lower and higher breakpoint concentrations are 4 and 8 mg/L, respectively.  156 
Although this may suggest the possibility of underreporting of tetracycline among many clinical 157 
isolates, in many cases with TetM mediated resistance results in high MIC values of greater than 32 158 
mg/L.  Exceptions to this have been noted in the situations of phenotypically susceptibleensitive strains 159 
which are tetM positive, but are only resistant following induction with antibiotic.14, 15  This anomaly 160 
would be missed by both commercial as well as CLSI approved protocols. With respect to testing for 161 
flouroquinolonefluoroquinolone resistance there are again inconsistencies with CLSI protocol.  The 162 
primary concern is the low threshold for ciprofloxacin breakpoints at 2 mg/L.  No agreed breakpoint 163 
was agreed for ciprofloxacin and it is known that a much higher concentration is required to inhibit 164 
growth of Ureaplasma than some of the newer third and fourth generation 165 
fluroquinolonesfluoroquinolones such as levofloxacin and moxifloxacin, respectively.  Although 166 
ofloxacin is not part of the CLSI recommended repertoire of fluoroquinolones, the breakpoint is the 167 
same as suggested for levofloxacin and moxifloxacin.  By taking these points into consideration it 168 
maybe that investigators identify false-negative ciprofloxacin isolates with susceptibility to either 169 
levofloxacin or moxifloxacin.   170 
 171 
Evaluation of studies reporting antibiotic resistance  172 
Antibiotic resistance is recognized as an international issue whereby resistant strains can be imported 173 
from countries with high levels of resistance.  For this reason, we carried out a review of the literature 174 
from the past ten years (2006 – 2016) to identify the number of studies examining resistance among 175 
Ureaplasma spp.  From this we identified 33 reports on clinical antibiotic resistance among Ureaplasma 176 
from a collection of single case reports as well as larger studies.6, 8, 12, 14-43  From these reports we 177 
extracted data regarding the year of publication, country in which the study was conducted, the patient 178 
group examined, methods by which AST was determined, whether the species of Ureaplasma was 179 
determined, number of isolates examined and finally, where relevant, the percentage of reported isolates 180 
resistant to antibiotics stated (Table 2). 181 
 182 
We identified, as expected, the rates of resistance varied by country and in some instances noted 183 
dramatic difference in reports from within the same country.  For example a study by Huang et al., 2016 184 
examined 1951 individuals and identified 54 % to be resistant to erythromycin.12  This is in contrast to 185 
the work by Song et al. and Ye et al., who examined 1513 and 15594 individuals with much lower rates 186 
of resistance at 11 % and 1%, respectively.39, 40  In some instances resistance was high to only a single 187 
class of antibiotic.  For example a study by Leli et al., found high levels of ofloxacin resistance (27.6%) 188 
among 152 Ureaplasma isolated in Italy, whereas no resistance any tetracycline or macrolide antibiotics 189 
were detected.29  The highest levels of fluoroquinolone resistance was documented in countries such as 190 
China with figures of 53 % of isolates resistant to ofloxacin and 88 % of isolates resistant to 191 
levofloxacin.12, 39  Resistance to tetracyclines were noted in high numbers in South Africa (73% of 192 
isolates),38 USA (34 % of isolates)27 and Cuba (31 % isolates).34  Many of these isolates were 193 
additionally confirmed for the presence of the tetM mobile genetic element. Of greatest concern in 194 
relation to treatment of neonatal infection are the high reported levels of macrolide resistance seen in 195 
certain countries. Using erythromycin as the indicator for resistance, as suggested by the CLSI, the 196 
highest levels of resistance were seen in Hungary (85 %),26 South Africa (80 %),38 Turkey (54 %),18 197 
China (54 %),12 Israel (46 %)25 and Cuba (46 %).34  Although these percentages are high in relation to 198 
countries such as the UK (0 - 2 %) or Croatia (0 – 7 %) there is a real possibility of clonal strains being 199 
introduced from countries of high resistance to those with low resistance.  Alternatively these levels 200 
reported may be an over representation as a result of the in accuracies of commercial assays as described 201 
previously. 202 
   203 
Use of the broth microdilution technique was as prevalent as the use of the Mycoplasma-IST kit (10/33 204 
studies and 11/33 studies, respectively).  However, as discussed earlier there are numerous limitations 205 
to commercial kits such as the Mycoplasma IST2, such as the incorporation of breakpoint levels which 206 
do not agree with CLSI guidelines.  This may have resulted in the over-reporting resistance for some 207 
antibiotics.    208 
 209 
Although Ureaplasma have been recognized as two separate species since 2000, there is still lack of 210 
discrimination at the species level.  Many of the diagnostic methods used in the literature review only 211 
report the presence of Ureaplasma and do not differentiate to the species level, partly due to culture 212 
based commercial kits, and in some incidences report U. urealyticum by default due to historic 213 
taxonomic reasons.  This reporting style has a negative impact on surveillance and understanding of 214 
distribution of resistant species as well as understanding the role of the two species in clinical outcome.  215 
For example the association between Ureaplasma and NGU has been controversial, but studies which 216 
have looked at Ureaplasma as two independent species have shown that U. urealyticum are significantly 217 
associated with NGU with an adjusted odds ratio of 2.3 compared with U. parvum (adjusted OR 0.4).44     218 
Nucleic acid technologies exist whereby species differentiation can be determined and should be 219 
adopted for any future reporting.45   220 
 221 
The role of Commercial kits in a clinical setting  222 
While the available commercial kits for M. hominis and Ureaplasma spp. detection and antibiotic 223 
susceptibility testing (in their current formats) may not provide publishable antibiotic resistance data 224 
without follow-up investigation, these kits provide an ideal method to investigate these emerging 225 
pathogens in a busy clinical setting.  Urethritis, inflammation of the urethra, is a common 226 
condition which is usually sexually acquired and commonly classified into those caused 227 
Neisseria gonorrhoea infection or other causes. The 2015 UK National Guideline on the 228 
management of non-gonococcal urethritis (NGU), published by the Clinical Effectiveness 229 
Group of the British Association for Sexual Health and HIV (Horner et al., 2015 doi: 230 
10.1177/0956462415586675) list ureaplasmas as one of the most common causes (11-26%) of 231 
NGU in men, only superseded by Chlamydia trachomatis (11-50%) and Mycoplasma 232 
genitalium (6-50%). Based on the guidelines, the first line treatment in outpatient clinics is 233 
with azithromycin (single dose of 1 gram) or doxycycline (100 mg/day for 7 days). These 234 
treatment levels were demonstrated to have similar efficacy in the past, 75% and 69%, 235 
respectively, against ureaplasmas (Manhart LE, Gillespie CW, Lowens MS, et al. Standard 236 
treatment regimens for nongonococcal urethritis have similar but declining cure rates: a 237 
randomized controlled trial. Clin Infect Dis 2013; 56: 934–942.; Khosropour CM, Manhart LE, 238 
Colombara DV, et al. Suboptimal adherence to doxycycline and treatment outcomes among 239 
men with non-gonococcal urethritis: a prospective cohort study. Sex Transm Infect 2014; 90: 240 
3–7.); however, as highlighted in table 1, inadvertent treatment of ureaplasmas is likely to 241 
decline with increasing global emergence of antimicrobial resistance. Furthermore, there is 242 
increasing evidence that treatment with a single 1 gram azithromycin dose drives development 243 
of mutations in the 23sRNA gene resulting in macrolide antimicrobial resistance in M. 244 
genitalium, [Bradshaw CS, Chen MY and Fairley CK. Persistence of Mycoplasma genitalium 245 
following azithromycin therapy. PLoS One [Electronic Resource]. 2008; 3: e3618.; Twin J, 246 
Jensen JS, Bradshaw CS, et al. Transmission and selection of macrolide resistant Mycoplasma 247 
genitalium infections detected by rapid high resolution melt analysis. PLoS One 2012; 7: 248 
e35593.; Ito S, Shimada Y, Yamaguchi Y, et al. Selection of Mycoplasma genitalium strains 249 
harbouring macrolide resistance-associated 23S rRNA mutations by treatment with a single 1 250 
g dose of azithromycin. Sex Transm Infect 2011; 87: 412–414.], which would likely also 251 
develop in the closely related ureaplasmas, and this may contribute to the failure of first line 252 
therapy to treat up to 25% of patients. Treatment of these recurrent urethritis patients, requires 253 
multiple follow-up appointments and may persist for up to a month with empirical treatment 254 
of up to 4 different antibiotics (macrolides, doxycycline, metronidazole, and fluoroquinolones) 255 
before it resolves.  256 
In the clinical setting, commercial kits provide reliable sensitive detection in 24-48 hours and 257 
give important guidance for therapeutic treatment in resistant infection. Furthermore, they 258 
require no specialist equipment, reagents or training.  Examination of the characteristics of all 259 
available kits, the latest generation of commercial kits available include the Myco Well D-One kit, 260 
which utilizes the CLSI breakpoints for antibiotic concentrations, and additionally specifically identify 261 
Gardnerella vaginalis, Trichomonas vaginalis and Candida albicans (all relevant to common 262 
genitourinary clinical investigation).  The advantage of this particular kit is that titration of 263 
microbial load by traditional methods for any positive sample, to ensure the inoculum tested 264 
was approximately 104 cfu, would ensure that the results were performed under CLSI-265 
compliant guidelines and therefore the results could be published. Ureaplasmas are also 266 
emerging as pathogens in other clinical settings as well: development of bronchopulmonary 267 
dysplasia (or chronic lung disease) in premature neonates [Viscardi and Kallapur doi: 268 
10.1016/j.clp.2015.08.003]; presence as the sole organism identified in histologically 269 
confirmed chorioamnionitis of moderate/late preterm and term placentae [Sweeney et al. 2016; 270 
doi: 10.1093/infdis/jiv587]; underlying cause of fatal hyperammonemia in lung transplant patients 271 
(Bharat et al., 2015); wound infection or absess formation in kidney transplant patients (Loupy et al, 272 
2008; Eilers et al., 2007); and meningitis in adults (Geissdorfer et al., 2008). Therefore, simplistic 273 
commercial kits that detect ureaplasmas and direct therapy may find expanding utility in 274 
clinical settings outside of genitourinary medicine.  275 
   276 
 277 
Concluding remarks 278 
This review has highlighted that there is a need for continual surveillance in order to keep track of 279 
resistance patterns.  Commercial kits are an easy way for an initial screening, but indication of resistance 280 
needs to be followed up appropriately, not just reported.  From this we suggest the following 281 
recommendations. 1) If a mixed M. hominis and Ureaplasma spp. culture is identified, isolation of 282 
single Ureaplasma colonies and repeat AST is required in order to obtain reliable data for macrolide 283 
resistance. 2) Confirm resistance with approved CLSI guidelines including quantifying the inoculum 284 
and/or 3) determine the underlying mechanism of resistance.  While it is tempting to attribute the low 285 
antibiotic resistance rates in some countries, such as the UK, to vigilance in prescribing polices and 286 
prudent use, the geographic differential in antibiotic resistance is unlikely to be maintained, particularly 287 
with the degree of travel between the countries of high levels and low levels of resistance in combination 288 
with the increased prescribing of macrolide antibiotics for N. gonorrhoeae, Chlamydia trachomatis and 289 
Mycoplasma genitalium infections.  The correct CLSI directed means of determining antibiotic 290 
susceptibilities, or determine the underlying mechanisms of resistance among Ureaplasmas ureaplasmas 291 
must be adhered to in order to produce reliable and comparable data for international surveillance. 292 
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445 
Product Supplier Quantification 
available* 
CLSI recommended antibiotics (minimum inhibitory concentration for resistance) 
Levofloxacin 
(≥>4 mg/L) 
Moxifloxacin 
(≥>4 mg/L) 
Tetracycline 
(≥>2 mg/L) 
Erythromycin 
(≥>16 mg/L) 
Telithromycin 
(≥>8 mg/L) 
MIST2 BioMérieux 104 and >104 1 and 4 N/A 4 and 8 1 and 4 N/A 
Complement 
Mycofast 
reveloutioN 
ELiTech 103, 104 and >105 1, 2 and 4** 0.25 and 2** 1, 2, 4 and 
8** 
8 and 16** N/A 
SIR Mycoplasma BioRad 102 – 104, 104 – 105 and 
>105 
N/A N/A 4 and 8 8 and 16** N/A 
Mycoplasma 
system plus  
Liofiolchem SLR <104, <105 and >105 N/A N/A 4 and 8 1 and 4 N/A 
MYCO WELL D-
ONE 
CPMI 104 and >105 2 and 4** 2 and 4** N/A 8 and 16** N/A 
Table 1. Compliance of commercial rapid diagnostic and antimicrobial susceptibility testing kits in comparison with Clinical Laboratory Standards 446 
Institute (CLSI) guidelines for Ureaplasma spp.. The antibiotics present represent those determined suitable for testing by the CLSI along with minimum 447 
inhibitory concentrations (MIC). N/A, not applicable. *All assays quantify by colony count independent methods. **CLSI compliant MIC ranges included for 448 
this antibiotic. 449 
  450 
Author 
(reference
) 
Year of 
publicati
on 
Country Patient group and 
sample type 
Method of 
susceptibil
ity testing 
Species 
determin
ed 
Numbe
r of 
isolates 
examin
ed 
Isolates resistant 
(Percent) 
DoxDO
X 
TetE
T 
MinMI
N 
CIPi
p 
OfxOF
X 
LVX
ev 
 
MoxM
OX 
AziA
ZI 
CLRla
ri 
EryER
Y 
RoxRO
X 
JosJO
S 
PriP
RI 
ClinC
LI 
Beeton (15) 2016 England 
and 
Wales 
Endotracheal 
aspirates from 
neonates, cervical 
swabs and patients 
with immunological 
disorders 
Broth 
microdiluti
on 
Yes 130 2 2 - 2 - 0 0 0 - 0 - - - - 
Huang (12) 2016 China Mix of fertile and 
infertile men 
Mycoplas
ma IST 
No 1951 5 - - 94 - 88 - 39 31 54 50 5 - - 
Schneider 
(43)
 
2015 Switzerla
nd 
Genital samples Mycoplas
ma IST2 
and Broth 
microdiluti
on 
Yes 103 0 0 - 19.4 9.7 - - 1 4.9 1.9 - 0 0 - 
Kawai (42) 2015 Japan  Vaginal and placental 
swabs and 
endotracheal 
aspirates from 
neonates 
Broth 
microdiluti
on 
Yes 28 - - - 93 
 
- 57 - - - - - - - - 
Messano 
(41)
 
2014 Italy Male urethral swabs Mycoplas
ma IST2 
No 115 2 2 - 36 16 - - 2 2 5 - 0 0 - 
Song* (40) 2014 China Mix of male urethral 
and female cervical 
swabs 
Mycoplas
ma IST2 
No 1513 0 - 3 1 - 4 - 64 – 
93 
44 - 77 - - 0 - 6 3 - 8 6 - 11 - 0 - 1 0 - 1 - 
Ye (39) 2014 China Female urogenital 
swabs 
Mycoplas
ma IST2 
No 15594 2 3 - 75 53 - - 0.1 0.1 1 - 0 0 - 
Redelingh
uys (38)  
2014 South 
Africa 
Females attending 
antenatal clinic self-
collected vaginal 
swabs 
Compleme
nt 
Mycofast 
revelutioN 
Yes 44 - 73 - - - 41 2 - - 80 - - - 100 
Vargovic 
(37)
 
2014 Croatia Male and female 
urogenital samples 
SIR 
Mycoplas
ma 
No 507 3 5 - - 22 - - 8 - 7 - - - 99 
Hunjak (36) 2014 Croatia Female urogenital 
samples 
Mycoplas
ma IST 2 
Yes 
 
424 0 0 - 35 5.2 - - 0.3 0 0 - 0 - - 
Pignanelli 
(35)
 
2014 Italy Women with 
cervicitis 
Mycoplas
ma IST 2 
No 899 2 3 - 40 6 - - 6 15 19 - 4 2 - 
Diaz (34) 2013 Cuba Women with vaginal 
discharge 
Mycoplas
ma System 
Plus 
No 
 
 
154 17 31 16 - 64 - - 30 63 46 - - - 18 
Ponyai (33) 2013 Hungary Swabs from male and 
female patients with 
non-gonococcal non-
chlamydial urethritis 
SIR 
Mycoplas
ma 
No 373 2 4 - - 25 - - 10 - 81 - - - 75 
Dhawan 
(32)
 
2012 India Males and females 
from a STD 
outpatients clinic 
Broth 
microdiluti
on 
 
Yes 35 9 - - - 23 - - 29 - - - 14 - - 
Mardassi 
(31)
 
2012 Tunisia Mixed patient group Broth 
microdiluti
on 
Yes 22 - 23 - - - - - - - - - - - - 
Govender 
(30)
 
2012 South 
Africa 
Female vaginal 
swabs from women at 
a termination of 
pregnancy clinic 
Broth 
microdiluti
on 
Yes 
 
15 13 33 - - 7 - - 13 - 27 - 0 
 
- - 
Leli (29) 2012 Italy Male and female 
urogenital samples 
(72 % were native, 
28% immigrant) 
Compleme
nt 
Mycofast 
revelutioN 
No 152 0 - - 66 28 - - 0 - 0 0 0 0 - 
Zhu (28) 2012 China Females with genital 
tract infections 
A 
commercia
l 
Mycoplas
ma strip  
No 1538 2 - 2 - 33 20 - 15 6 - 33 12 - - 
Xiao (27) 2012 USA Variety of clinical 
isolates between 
1997 - 2011 
Broth 
microdiluti
on 
Yes 257 - 34 - - - 5 - - - 1 - - - - 
Farkas (26) 2011 Hungry Male and female 
urogenital swabs  
SIR 
Mycoplas
ma 
No 247 5 6 - - 21 - - 12 - 85 - 10 - 79 
Samra (25) 2011 Israel Various GUM 
samples 
Broth 
microdiluti
on 
No 63 3 3 - - - 0 0 13 0 46 25 - - - 
Goulenok 
(24)
 
2011 France Systemic lupus 
erythematosus 
Not state No 1 (Case 
study) 
Susens Suse
ns 
- - - - - - - - - - - - 
patient  without 
Hypogammaglobulin
emia 
Mihai (23) 2011 Romania Endocervical swabs 
from infertile women  
Mycoplas
ma IST2 
No 372 2 6 - 52 16 - - 8 9 16 - 2 3 - 
Biran (22) 2010 France Term neonate with 
CSF infection 
Not stated Yes 1 
(Case 
study) 
- - - Res - - Susens - - - - - - - 
Lucke (21) 2010 Switzerla
nd 
Sternal wound 
infection 
Mycoplas
ma IST2 
Yes 1 (Case 
study) 
Susens Suse
ns 
- Res Int - - Susen
s 
Susens Susens - Susen
s 
Susen
s 
- 
Krausse (20) 2010 Germany Mixed patient group 
and sample 
Agar 
dilution 
and E-test 
No 179 1 3 3 16 2 - - 7 5 21 6 2 - 43 
Beeton (6) 2009 UK Neonatal lavage fluid Broth 
microdiluti
on 
Yes 61 2 2 - 2 - - - 2 2 2 - - - - 
Kechagia 
(19)
 
2008 Greece Vaginal swabs from 
women aged 18-62 
Mycoplas
ma IST2 
No 111 0 5 - 86 20 - - 9 7 37 - 0 9 - 
Geissdörfe
r (8) 
2008 Germany Adult male with 
Ureaplasma 
meningitis 
Mycoplas
ma IST2 
Yes 1 (Case 
study) 
- - - Res Int - Int - - - - - - - 
Dégrange 
(14)
 
2008 France Patients in Bordeaux, 
France 
SIR 
Mycoplas
ma 
No 276 2 2 2 - - - - - - - - - - - 
Karabay 
(18)
 
2006 Turkey Women with 
abnormal vaginal 
discharge 
 No 193 2 14 - 41 58 - - - - 54 - 2 8 - 
Xie* (17) 2006 China Samples from 
outpatients clinic 
Mycoplas
ma IST2 
No 804 4 
 to 
11 
5 
to 
 12 
- 82 
 to 
89 
24 
to 
67 
- - 15 
to 
23 
17 
 to  
 28 
11 
 to  
64 
- 0 
 to  
3 
0 
 to  
5 
- 
Duffy (16) 2006 USA Chronic bladder 
infection 
Broth 
microdiluti
on 
Yes 1 (Case 
study) 
Susens - - - Res Res Res - - Susens - - - - 
Table 2. Summary of global antibiotic resistance among Ureaplasma isolates from 2006 to 2016. 451 
Dox DOX – Doxycycline, Tet TET – Tetracycline, Min MIN – Minocycline, CIPip – Ciprofloxacin, OFXfx – Ofloxacin, LevVX – Levofloxacin, 452 
Mox MOX – Moxifloxacin, Azi AZI – Azithromycin, CLRlari – Clarithromycin, Ery ERY – Erythromycin, Rox ROX – Roxithromycin,  Jos JOS 453 
– Josamycin, Pri PRI – Pristinamycin, CLIlin – Clindamycin. Res = Resistant, Int = Intermediate and Susens = SensitiveSusceptible. - Not 454 
determined . *Incidence of resistance was broken down by year with the lowest and highest percentages recorded. 455 
 456 
 457 
